Type 2 diabetes is characterized by a loss of glucose homeostasis, caused by insufficient insulin secretion from pancreatic beta-cells, and development of insulin resistance in target cells of muscle, liver and adipose tissue. Recent advances have demonstrated how obesity-related low-level chronic inflammation contributes to insulin resistance, and complement has been implicated in this process. On the other hand, homeostatic auto-/para-crine or even intracellular complement has been implicated in metabolic signaling and proper function of beta-cells and insulin secretion. In addition, diabetes leads to peripheral complications including nephropathy, retinopathy, and neuropathy, affecting tissues which are all also sensitive to complement attack, as demonstrated by human deficiencies and GWAS studies.
View agenda & speakers
The field of complement drug discovery has never been riper with opportunities for therapeutic intervention in diverse clinical indications. 14 years after the clinical approval of the first complement-specific drug, eculizumab, the complement drug space has garnered renewed interest owing to a series of game-changing clinical developments. The recent clinical approval of the first compstatin-based C3-targeted therapeutic for treating PNH and the approval of a small-molecule C5aR1 antagonist for severe ANCA-associated vasculitis have expanded the clinical arsenal of complement therapeutics bringing tailored complement intervention closer to fruition and bolstering confidence in the broader therapeutic scope of complement inhibitors.
Embracing these important developments, we are delighted to announce the 15th International Conference on Complement Therapeutics which will bring together leading experts from academia, the biopharma industry and drug regulatory agencies to discuss the latest developments in complement therapeutics, clinical trials and new aspects of complement-driven pathophysiology in emerging indications. Topics will include: Molecular mechanisms and targets in complement-related diseases; Novel inhibitors & pipeline compounds; Hematological disorders; Organ & cell transplantation, I/R injury and chronic rejection; Kidney diseases; Neurological & ocular diseases; Acute and chronic inflammatory disorders; Infectious diseases & COVID-19; complement targeting in cancer immunotherapy; complement biomarkers in disease diagnosis and therapy; Novel and unexpected indications.
The antibody response and the complement system are major effector arms of the immune system. Both have been involved in a plethora of pathological conditions—including autoimmunity, allergy, infections and cancer—and regulate, mainly through their receptors (FcR and CR respectively) cell activation, migration, survival but also metabolism. As the portfolio of antibody—and complement-effector function grow, high-end technological solutions are developed and novel therapeutic applications are proposed.
This 3rd meeting of the Ab&Complement meeting series will focus attention on key advances in both fields with the aim at fostering discussions between antibody experts and complement experts. Some of the critical topics to be covered include antibody & complement functions, FcR and CR, Ab glycosylation and anti-inflammatory activity, Structure-function linkage, Novel technologies, complement and antibody therapies.
This meeting on Antibody & Complement will be a forum for leaders in the field and new investigators coming from academia, industry and research institutes to discuss where the field is going and what challenges lie ahead.
We cordially invite you to Lübeck, the Queen of the Hanseatic League, to attend the 19th European Meeting on Complement in Human Diseases (EMCHD2024) from September 2-6, 2024. The meeting will focus on recent developments in the complement field that translate basic scientific advancements into novel therapeutic approaches to combat human diseases.
SAVE THE DATES!
ICW 2025 WORKSHOP
September 14-19, 2025
Complement...we are the experts!